Inovio Pharmaceuticals (INO) PT Set at $13.00 by HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) has been given a $13.00 price target by equities research analysts at HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 157.94% from the stock’s previous close.

Several other equities analysts have also commented on INO. Maxim Group dropped their target price on Inovio Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, February 15th. BidaskClub upgraded Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. ValuEngine lowered Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Finally, Royal Bank of Canada upped their target price on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a research note on Thursday, March 15th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Inovio Pharmaceuticals currently has an average rating of “Buy” and an average target price of $11.59.

NASDAQ INO opened at $5.04 on Wednesday. Inovio Pharmaceuticals has a fifty-two week low of $5.02 and a fifty-two week high of $5.11. The firm has a market capitalization of $454.81 million, a PE ratio of -4.62 and a beta of 2.52.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.22). Inovio Pharmaceuticals had a negative return on equity of 72.04% and a negative net margin of 292.06%. The company had revenue of $1.53 million during the quarter, compared to analyst estimates of $7.50 million. During the same period last year, the firm earned ($0.31) earnings per share. equities research analysts anticipate that Inovio Pharmaceuticals will post -1.2 EPS for the current year.

In other news, Director David B. Weiner sold 9,000 shares of the company’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $4.91, for a total value of $44,190.00. Following the completion of the sale, the director now owns 758,956 shares of the company’s stock, valued at $3,726,473.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jong Joseph Kim sold 103,750 shares of the company’s stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $5.14, for a total value of $533,275.00. Following the completion of the sale, the chief executive officer now directly owns 2,395,557 shares of the company’s stock, valued at approximately $12,313,162.98. The disclosure for this sale can be found here. Insiders sold 116,500 shares of company stock valued at $597,078 over the last quarter. Insiders own 9.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of INO. Wells Fargo & Company MN boosted its position in shares of Inovio Pharmaceuticals by 16.1% in the third quarter. Wells Fargo & Company MN now owns 103,680 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 14,342 shares during the period. Bank of Montreal Can boosted its position in shares of Inovio Pharmaceuticals by 15.5% in the fourth quarter. Bank of Montreal Can now owns 212,108 shares of the biopharmaceutical company’s stock worth $876,000 after buying an additional 28,400 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of Inovio Pharmaceuticals in the fourth quarter worth about $120,000. Virtus Fund Advisers LLC purchased a new stake in shares of Inovio Pharmaceuticals in the fourth quarter worth about $334,000. Finally, ARK Investment Management LLC boosted its position in shares of Inovio Pharmaceuticals by 99.7% in the fourth quarter. ARK Investment Management LLC now owns 286,277 shares of the biopharmaceutical company’s stock worth $1,182,000 after buying an additional 142,894 shares during the period. 31.34% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit